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Materials and Methods
Rett syndrome (RTT) is a X- dominant neurodevelopment disorder that affects females almost exclusively and the prevalence
is approximately 1 in 10.000 live female births. About 90% of classical RTT cases are caused by mutations in Methyl-CpG
binding protein 2 (MECP2) gene located in the locus Xq28. Patients with classic form seem to develop normally until 6-18
months old and then they start a regression of acquired activities, such as voluntary use of hands, lose speech, but also
develop microcephaly, stereotypic hand movements, respiratory irregularities, and autism behaviour.
The aims of this study are to present a view of Rett syndrome’s research and to expose the preclinical gene therapy trials
published, in order to discuss the eficiency of this therapy and its possible aplication in humans.
Introduction
Results
MeCP2 is critical for the neurodevelopment and the maintenance of
mature neurons. The most important domains of MeCP2 are MBD and
TRD, essential for doing its function. Figure 1. a) A diagram of
MECP2 gene, that
contains 4 exons. In
colours there is the
representation of each
protein domain in the
gene sequence. MECP2
also contain 2 start
codons that leads to an
a)
b)
Animal model Generation Phenotype
MeCP2tm1.1 Bird (Mecp2-null
mice)
Deletion of exons 3 and 4 of Mecp2
by Cre system.
Normal until 6 weeks of age. After that,
mutant mice developed motor impairments,
irregular breathing, decreased body and
brain weight, reduced neuronal size and
had a premature lethality. Heterozygous
females mice develop similar features but
take longer to achieve it.
MeCP2tm1.1 Jae (Mecp2-null
mice)
Deletion of exon 3 of Mecp2 by Cre
system.
MeCP2308-mice (MeCP2-
null mice)
Generation of a truncated Mecp2 by
the introduction of a premature STOP
codon.
Male mutant mice exhibited RTT-like
phenotype; in contrast, heterozygous
females develop a milder phenotype.
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alternative splicing. b)
Owing to alternative
splicing two isoforms are
generated: MeCP2-e1
and MeCP2-e2. MeCP2-
e1 is more abundant in
brain [1].NTD: N-terminal domain; MBD: Methyl binding domain; ID: intervening domain;TRD: transcriptional repressor domain.; CTD: C-terminal domain
MeCP2 disruption in
Rhesus and
Cynomologus monkeys
TALENT-mediated mutagenesis into
exon 3 of Mecp2.
Male monkeys die in midgestation. One
heterozygous female survive and was
apparently normal at 4 months after birth.
MeCP2Q63*/Q63* (MeCP2-
null zebrafish)
Production of a non-sense mutation
in Mecp2 that leads to a truncated
protein at position 6.
Weak phenotype with no alterations apart
from a shorter lifespan and some motor
impairment.
NSC derived from adult
Mecp2tm1.1Bird - mouse
Figure 2. Retrovirues constructs use to transfect Neuronal stem
cells (NSC) [2].
Figure 3. Differentiated NSC (14 days) from Mecp2tm1.1Bird+/- female
mouse. Non-infected cells show mosaic Mecp2 (endogenous)
Survival
Motor phenotype
Nuclear volume
Figure 5. AVV9/CBA construct use to infect Mecp2tm1.1Bird male mice [3].
Figure 6.
Neonatal male
mice were
bilateral injected
into brain [3].
Figure 7. Widespread
exogenous expression of
There are three primary studies demonstrating the possible delivery of MeCP2 into the brain cells of Mecp2-deficiency mice (“in vitro” and “in vivo”)
Figure 9. scAVV9/Mecp2 construct use to
infect Mecp2tm1.1Bird mice [4].
Intravenous delivery
into 4-6 weeks-old mice
scAAV9/MeCP2 injection resulted in a MeCP2
expression similar to endogenous levels throughout the
brain.
Conclusions
expression. Cells transfected (Retro-EF1α-E1 and Retro-MeP-E1)
express exogenous MeCP2-E1 (Myc-tag). [2].
Figure 4. NSC from Mecp2tm1.1Bird+/- mice were differentiated for
3 weeks. For dendrite maturation analysis, NSC were stained
for MeCP2 (green), DAPI (blue) and neuronal marker Tubulin
III (red) [2].
In comparison to control NSC, infected NSC
(Retro-EF1α-E1) exhibit longer primary
dendrites, occasionally secondary dendrites and
neuronal networks began to be formed.
Introduced by intravenous delivery
into four - five week-old
Mecp2tm1.1Bird male mice
In intravenous delivery in juvenile male mice, the proportion
of cells transduced was lower and the benefit is more limited.
MeCP2 through the
brain. White arrow
indicates the injection
site. Proportion of Myc
relative to NeuN
population [3].
Figure 8. AVV9/MeP construct
use to infect Mecp2tm1.1Bird
male mice [3].
Figure 11. Survival percentage of MeCP2
positive, negative and wild-type mice [4].
Figure 10. Average soma
diameters of pyramidal cells
(CA3) of MeCP2 positive,
negative and wild-type mice [4].
The results in behaviour and motor test for
these female injected mice were similar as wild-
type mice. However, alterations in respiration
were the only point that was not clear, since
some injected females present alterations.
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• Administration of MECP2 through an AAV9 construct into Mecp2-dificient mice improves the phenotype and
prolongs their lifespan.
• Neurons showed in transfected animals exhibit wild-type size, density and dendritic branch.
• Positive results suggest that gene therapy for RTT-patients is a challenge that could be achieved in the future.
However, the investigation has to continue and new studies with big animals and trying new constructs, in order to
accurate the therapy, have to be done.
